A new study from the Salk Institute has revealed that a protein called BCL6 is key to maintaining healthy muscle mass. The experiments showed that mice with lower levels of BCL6 had significantly ...

ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade the BCL6 protein, a key driver of B-cell lymphomas. ARV-393 shows strong synergistic antitumor activity ...

Additional detail on the ARV-393 data presentation at AACR 2025: Poster Title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader ... B-cell lymphoma 6 protein (“BCL6 ...

One of these proteins, BCL6, when mutated, drives the blood cancer known as diffuse large cell B-cell lymphoma. This kind of cancer-driving protein is also referred to as an oncogene. In lymphoma ...

p 0.05; ***p ? 0.001. (D) Tumor BCL6 protein levels were determined using IHC analysis. Representative images of BCL6 IHC staining in SU-DHL-4 tumors are shown. Scale bars 100 μm. (E ...

The data suggest that ARV-393, a PROteolysis TArgeting Chimera (PROTAC) designed to degrade the B-cell lymphoma 6 protein (BCL6), may effectively combine with existing lymphoma treatments to ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...